ライフサイエンスコーパス: surface marker

1 erapeutically targeting CSC base sorely on a surface marker.

2 r glycoprotein 2 (GP2) as a PP-specific cell surface marker.

3 h17 cells in vitro and in vivo via CD25 cell surface marker.

4 some biology is to sort exosomes by size and surface markers.

5 lly purified from the bone marrow using cell surface markers.

6 progenitor cells that express analogous cell-surface markers.

7 metry by relative cell size, granularity and surface markers.

8 ter of blood and the fold expression of cell surface markers.

9 of nontransgenic mice using CD31 and CD13 as surface markers.

10 fetal pancreatic differentiation using cell surface markers.

11 mited by the lack of available specific cell surface markers.

12 ield APHs that specifically target different surface markers.

13 s from mouse and human tissues based on cell surface markers.

14 of module 20 in recognizing polyanionic self-surface markers.

15 ed progenitors independently of conventional surface markers.

16 rve, and immunofluorescence staining of cell surface markers.

17 eg from nT reg cells in vivo based solely on surface markers.

18 try together with various hematopoietic cell surface markers.

19 sult of context-dependent expression of cell surface markers.

20 challenging due to the lack of specific cell surface markers.

21 eton regulators and the localization of cell surface markers.

22 RNA, intracellular p24 Gag protein, and cell surface markers.

23 sed manner a panel of all commonly used cell surface markers (280 genes) from individual cells.

24 We show herein that the cell surface marker 6-sulfo LacNAc (slan) can define slan-pos

25 iral haemagglutinin (HA) expression and cell surface markers 8-16 hours post infection.

26 or cells based on their expression of unique surface markers, abilities to form spheres under nonadhe

27 expressed higher levels of more mature cell surface markers, additionally linking inflammasome activ

28 ere assessed by measuring expression of cell surface markers (adhesion molecules, fibrinogen-like pro

29 These cell surface markers allowed direct isolation of rare cells f

30 We compared different combinations of surface markers among ISCs isolated based on expression

31 technique is reproducible and scalable, and surface marker analysis by bead-based flow cytometry rev

32 Gene expression signature and surface marker analysis have indicated that NEMs represe

33 Subsequent surface marker analysis revealed higher frequencies of C

34 melanoma cell adhesion molecule (MCAM) is a surface marker and adhesion molecule used by pathogenic

35 n this study, we define distinct patterns of surface marker and cytokine expression among the ILC sub

36 we identified GD2 as a new CSC-specific cell surface marker and GD3S as a potential therapeutic targe

37 healthy control donors share a similar cell-surface marker and gene expression profile.

38 al cells expressed specific endothelial cell surface markers and also exhibited the capacity for cell

39 labelling of cell populations based on their surface markers and applied it to labelling of the Feder

40 wn to express the LC-specific TROP-2 and Axl surface markers and contained Birbeck granules.

41 not only induces characteristic patterns of surface markers and cytokine production but also has a m

42 Based on their unique surface markers and cytokine profiles, these cells were

43 also expressed a mixed M1 and M2 profile of surface markers and cytokines/chemokines upon infection

44 he thymus and identifiable by characteristic surface markers and DNA methylation.

45 Induced erythroblasts expressed erythroid surface markers and formed erythroid colonies.

46 Combined use of surface markers and functional assays to study CD4(+) T

47 ised of distinct subsets with different cell surface markers and functional characteristics and this

48 al dendritic cells (cDCs) with distinct cell surface markers and functions exist in mouse and human.

49 lay significantly altered expression of cell-surface markers and produce increased inflammatory cytok

50 nd short-lived and express basophil-specific surface markers and proteases.

51 (iv) expression of endothelial cell-specific surface markers and the absence of hematopoietic or myel

52 These cells express surface markers and transcription factors associated wit

53 ed mass cytometry including a broad range of surface markers and transcription factors to accurately

54 With the accumulation of various surface markers and transgenic mouse models, we have bee

55 likeness extended into the non-ISCT MSC cell surface markers and trilineage differentiation, which we

56 by accumulation of proliferating cells with surface markers and ultrastructural features similar to

57 eutrophil morphology (nucleus shape and cell-surface markers) and functions (phagocytosis, degranulat

58 (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediated des

59 y for measuring cell entity, evaluating cell surface marker, and peculiarly in the field of stem cell

60 lyzed for suppressor activity, expression of surface markers, and cytokine secretion profiles.

61 Finally, changes in cellular metabolism, surface markers, and gene expression, but not miRNA prof

62 ding those encoding effector cytokines, cell surface markers, and key transcription factors.

63 IFN-alpha/IFN-beta levels, surface markers, and T-cell stimulatory function were in

64 trophoblast progenitors, purified using the surface marker APA.

65 itical step which has proven difficult using surface-marker approaches.

66 Because many cell surface markers are shared between AML blasts and health

67 bodies that can analyse cells by using their surface markers as inputs.

68 should preferably not rely on tumor-specific surface markers, as these are only available in a limite

69 dicated by bronchoalveolar lavage eosinophil surface markers, as well as the release of eosinophil pe

70 tion of functional HLCs using the hepatocyte surface marker asialoglycoprotein receptor 1 (ASGR1).

71 We identified surface markers associated with each chromatin state tha

72 lls in part by increasing the levels of cell surface markers associated with mesenchymal stem cells.

73 Importantly, PC-M cells expressed surface markers associated with pericytes.

74 We identified cell surface markers associated with repression of p16(INK4a)

75 y of human Tregs using an extensive panel of surface markers associated with Treg function and phenot

76 he aim of this investigation was to identify surface markers associated with type 2 inflammation.

77 Surface-marker-based detection of CTC predicts recurrenc

78 biosensor that can identify a specific cell surface marker by targeted (129)Xe MRI.

79 This requires delineating the expression of surface markers by DC subsets among individuals and tiss

80 lentiviral vectors (LVs) targeted to the EC surface marker CD105 for in vivo gene delivery.

81 Additionally the expression of distinct surface markers (CD106, CD162 and myeloperoxidase MPO) w

82 YFP(+) BMCs shared surface markers (CD11b+Gr1+Ly6C+Ly6G-F4/80(low)) with mo

83 of similar size-AP-1060 and NALM-1-based on surface markers CD13 and HLA-DR.

84 The cell surface marker CD133 is frequently used to identify TICs

85 Currently, the cell surface marker CD138 (SDC1) is used for this enrichment,

86 3 for 48 h showed no alterations in the cell surface markers CD14, CD86, CD83, CD207, E-cadherin, CD8

87 12L colocalized to cells that expressed MDSC surface markers CD15+CD33+HLA-DRlo.

88 a from vaccinated infected mice exhibited M2 surface markers (CD16, CD32, CD200, and CD206), moderate

89 d flow cytometry analyses confirmed that the surface marker CD2 was expressed at higher levels on lat

90 in K562 leukemic cells, we identify the cell surface marker CD24 as co-varying with chromatin accessi

91 least five distinct cell states based on two surface markers (CD24 and EPCAM) and provides a gating s

92 h great thermogenic potential using the cell surface marker CD29.

93 ), spleen and thymus were labeled for T cell surface markers (CD3, CD4, CD8) and intracellular Foxp3;

94 ding CTNND1 and the early hematopoietic cell surface marker CD34, resulted in reduced leukemic growth

95 eron-gamma with a unique combination of cell surface markers (CD4(+)CD25(-)CD44(hi)CD62L(lo)) and tra

96 The surface marker CD44 has been identified as one of severa

97 m cell-like characteristics express the cell surface marker CD44.

98 e transitions, marked by changes in the cell-surface markers CD44 and ICAM1, and a Nanog-enhanced gre

99 xpress IL-10, as well as Tr1-associated cell surface markers, CD49b and LAG-3, and transcription fact

100 ing and characterization, we identified that surface markers CD49f, CD61 and ESA were aberrantly over

101 suppressing the expression of co-stimulatory surface markers CD80 and CD86.

102 low nanomolar range, we identified the cell surface marker CD86 as a sensitive surrogate biomarker o

103 are also characterized by expression of the surface marker CEACAM6.

104 sed on a variety of phenotypes, such as cell surface markers, cell proliferation and drug response.

105 Specifically, the expression of surface markers characteristic for MZ B cells was altere

106 pressing population that lacks hematopoietic surface markers, cocultured with AGM AKT-ECs specified i

107 ein expression of TIGIT and FCRL3 as a novel surface marker combination that distinguishes Helios(+)F

108 ll line that we termed PC-A, which expressed surface markers common to mesenchymal stromal cells.

109 B cells expressed B surface markers compatible with a marginal zone origin.

110 s of HPCs examined, including HPCs with cell surface markers consistent with immature hematopoietic s

111 signatures, morphological changes, and cell surface markers consistent with myeloid maturation.

112 munotherapy had higher expression of the TH2 surface marker CRTH2 (P = .04) and lower expression of t

113 ls (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that th

114 in the tumor preferentially express the cell surface markers CTLA-4 and OX40.

115 characterized by the expression of the cell surface marker CXCR4.

116 Surface markers, cytokines, and transcriptional characte

117 ed study has been hampered by a lack of cell surface markers defining tumor-specific dysfunctional TI

118 However, a suitable surface marker distinguishing the phenotypically overlap

119 Forty cell-surface markers, distinguishing all major leukocyte popu

120 proach is that the presence of specific cell surface markers does not directly reflect the transcript

121 cell (CTC) detection strategies rely on cell surface marker EpCAM and intracellular cytokeratins (CKs

122 , we showed that the pluripotency associated surface marker, epithelial cell adhesion molecule (EpCAM

123 CXCL10, CXCL12, CXCL13 and CXCL16) and cell surface marker expression (CD3, CD4 and CXCR3) in periph

124 adherence to plastic inevitably changes the surface marker expression and biological properties of t

125 eral blood, cutaneous mTregs had unique cell surface marker expression and cytokine production.

126 ation, cells were characterized through cell-surface marker expression and lineage-specific different

127 uced differentiation into MPhis with high M2 surface marker expression and production of pro- and ant

128 ontrol iDCs to WT capsule did not alter cell surface marker expression but did elicit IL-8.

129 Surface marker expression by polyp cells was determined

130 mmatory cytokine secretion and costimulatory surface marker expression in both cell types; an miR-155

131 esigned a flow cytometry panel that utilises surface marker expression observed in standard 2D erythr

132 Surface marker expression of CD11b+ myeloid cells was al

133 regardless of methodology for harvest, cell-surface marker expression of CD73, CD90, CD105, and Stro

134 rization which profiles CCSCs based on their surface marker expression phenotypes.

135 Gene and surface marker expression suggest that splenic CD8 cell

136 assified in accordance with their respective surface marker expression via completely distinct Raman

137 vivo, and except for CD138, plasmablast cell surface marker expression was unaffected.

138 but retained memory characteristics, such as surface marker expression, a lower metabolic rate, and i

139 y means of mass cytometry simultaneously for surface marker expression, activation states of intracel

140 roliferation responses, alloreactivity, cell surface marker expression, and antibody production.

141 vely increased polyploidization, mature cell-surface marker expression, and apoptosis of malignant me

142 ll morphology, LPS-induced cytokine profile, surface marker expression, and phagocytosis rate of apop

143 ls showed convergence in the pattern of cell surface marker expression, cytokine profiles, and gene e

144 addition, Cardif(-/-) NK cells have altered surface marker expression, lower cytotoxicity, decreased

145 hen isolated from skeletal muscle using cell surface marker expression, these cells showed comparable

146 e characterized into subtypes based on their surface marker expression, which affects their prognosis

147 the decrease in cytokine production and cell surface marker expression.

148 ons influence human neutrophil migration and surface marker expression.

149 with reduced IL-6 secretion, and normalised surface marker expression.

150 d into two different subpopulations based on surface marker expression: CD14/16 and Ly6C/CX3CR1, resp

151 Cell surface markers' expression and chemotaxis were determin

152 Cell, Prashad et al. (2014) describe a novel surface marker for human fetal liver HSCs, glycosylphosp

153 In an effort to find a more specific surface marker for malignant SS cells, a microarray anal

154 r (MC1R), which has been evaluated as a cell-surface marker for melanoma.

155 phere formation, and reexpression of CD24 (a surface marker for non-CSCs), concomitant with an epithe

156 ation during cancer immunotherapy and a cell-surface marker for pancreatic cancer.

157 We further identified a cell surface marker for prospective isolation of iNCs, which

158 stem cells, and it is widely used as a cell surface marker for the isolation and characterization of

159 eukin 2, and tumor necrosis factor alpha and surface markers for differentiation (CD127) and anergy (

160 Existing cell surface markers for GSC are developed from embryonic or

161 tified band 3 and alpha4 integrin as optimal surface markers for isolating 5 morphologically distinct

162 ine triphosphate and ultraviolet/fluorescent surface markers for monitoring.

163 proach facilitates the rational selection of surface markers for prospective isolation of cell subpop

164 Cell-surface markers for prospective isolation of stem cells

165 Thus, we identify novel surface markers for the consistent identification and is

166 ing process, and led to the discovery of new surface markers for the enrichment of iCMs.

167 ies in the periphery, and so far appropriate surface markers for their precise identification are mis

168 , each of which is characterized by specific surface markers, gene-expression patterns, and distinct

169 the hallmarks of stem cells, including cell surface markers, global gene expression profiles, and in

170 both targeting the erythrocyte-specific cell surface marker glycophorin A.

171 ere found to express the characteristic MDSC surface markers Gr-1 and CD11b in mice or CD11bc and His

172 However, to date, not a single surface marker has been identified as a common marker ex

173 To date, the lack of AML-specific surface markers has impeded development of such CAR-base

174 basis of the differential expression of cell-surface markers, here we identify a mesenchymal stromal

175 ic and transcriptional profiling, as well as surface marker identification of single circulating tumo

176 haracteristics, including nuclear structure, surface markers, IL-5 independence, and immunoregulatory

177 to the impaired expression of relevant cell surface markers in Eklf(-/-) erythroid cells.

178 ules CXCR6 and CD49a have been identified as surface markers in mice.

179 urce to assist the functional exploration of surface markers in normal and malignant lymphopoiesis.

180 infection, we analyzed a panel of macrophage surface markers in skin biopsy specimens of pustules obt

181 Persistence of respective cell surface markers in vitro is confirmed both by flow cytom

182 nses, alloreactivity, and expression of cell surface markers in vitro.

183 ction using an optimized combination of cell surface markers including CD30.

184 that exhibit differential expression of cell surface markers, including CD105 (or endoglin), Thy1 [or

185 consisted of NK cells expressing a range of surface markers, including CD56(hi) and CD56(low) NK cel

186 gramming-prone cells express a unique set of surface markers, including CD73, CD49d and CD200, that a

187 Nonetheless, well-characterized surface markers, including MerTK and FcgammaR1 (CD64), a

188 , the PNVs were able to induce expression of surface markers indicative of DC activation and maturati

189 Expression of regulatory B-cell-associated surface markers, interleukin-10, chemokine receptors, an

190 coupled to affinity moieties that target GI surface markers involved in transport, may improve this

191 lammatory cell numbers and cytokine and cell-surface marker levels on monocytes and macrophages.

192 Gene expression analysis identified distinct surface markers like CD226 and revealed that the transcr

193 stem cells (MaSCs) using combinatorial cell surface markers (Lin(-)CD24(+)CD29(h)CD49f(h)) has impro

194 or the specific recognition of the bacterial surface markers lipopolysaccharide (LPS) and lipoteichoi

195 n based on the expression profiles of 2 cell-surface markers LNGFR (CD271) and THY-1 (CD90).

196 xosomes share similar characteristics (size, surface marker, miRNA content) with previously described

197 dly upregulate the expression of the NK cell-surface marker NK1.1 in response to MSU crystals but not

198 acrophages have elevated expression of these surface markers, not microglia.

199 rotein A repetitions predominant (GARP) is a surface marker of activated regulatory T cells.

200 known as CD143), a recently identified cell-surface marker of adult human hematopoietic stem cells,

201 We have found that the canonical surface marker of ASCs, CD138 (syndecan-1), which is upr

202 CD44 is commonly used as a cell surface marker of cancer stem-like cells in epithelial t

203 E-selectin is a surface marker of endothelial cell (EC) inflammation, on

204 sion of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.

205 1(+) cluster, revealed it to be a novel cell surface marker of human epidermal stem cells.

206 ransduced with a CAR targeting CD5, a common surface marker of normal and neoplastic T cells, undergo

207 CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of cl

208 ceptor alpha subunit (IL-11Ralpha) as a cell surface marker of tumor progression that correlates with

209 in these cell lines simultaneously expressed surface markers of both NE and ML differentiation, confi

210 In addition to identifying surface markers of eHAV vesicles, the results support an

211 sorders, yet there are few, if any, reliable surface markers of eosinophil activation.

212 cytokine production, proliferation, and cell surface markers of immune cells between GA-treated and P

213 Previous attempts to identify surface markers of intermediate cell populations were ba

214 We sought to identify reliable surface markers of ISCs and establish a robust functiona

215 munohistochemistry for CD45, CD3, and CD163, surface markers of leukocytes, T cells, and activated ma

216 Cells with surface markers of long term HSC increased the expressio

217 polysaccharide (LPS)-induced upregulation of surface markers of MDDC maturation and did not prevent L

218 We analyzed surface markers of MDSCs in peripheral blood and at the

219 were established and characterized for cell surface markers of mesenchymal stem cell origin in conju

220 notation, these loci included genes encoding surface markers of myeloid, lymphoid, or hematopoietic s

221 Here we report that hybrid cells expressing surface markers of neutrophils (Ly6G, L-selectin, CXC ch

222 d for the presence of CD24, CD44, and CD326: surface markers of pancreatic CSCs.

223 Cell type-specific surface markers offer a powerful tool for purifying defi

224 We measured expression of the CD161 surface marker on splenocytes in SHRs and normotensive c

225 leukocyte antigens, blood group antigens are surface markers on the erythrocyte cell membrane whose s

226 We found that expression of surface markers on these DC was similar to that of CD8(-

227 from femur and tibia, and the expression of surface markers on YFP(+) BMCs was analyzed by flow cyto

228 SCs) can be identified by expression of cell surface markers or enzymatic activity, but these methods

229 cellular adhesion, without knowledge of cell-surface markers or intracellular proteins.

230 ing approaches that are limited by available surface markers or selectable metabolic characteristics,

231 he heterogeneity in renal DC populations and surface marker overlap with monocytes/macrophages has ma

232 y of CD28(-) T cells that expressed the CD56 surface marker (patients, 34.9% vs. aged controls, 25.8%

233 orcine alveolar macrophage (PAM) in terms of surface marker phenotype, susceptibility to ASFV infecti

234 teristics such as cell cycle status and cell surface marker phenotype, they respond to different extr

235 was confirmed by examining cytokine and cell surface marker production in bone-marrow-derived dendrit

236 CBSCs possess a unique surface marker profile, including high expression of CD6

237 n high numbers for months and maintain their surface marker profile, indicating that this population

238 re cells characterized by a CD44+/CD24- cell surface marker profile.

239 However, stress had no effect on lymphocyte surface marker profiles in both donor and recipient mice

240 ct from IFN-gamma producers, despite similar surface marker profiles.

241 rophils and endothelial cells is involved in surface marker regulation and thus chemotaxis of neutrop

242 These cells secrete IL-4 and IFN-gamma, and surface markers revealed significantly elevated frequenc

243 Instead, in a systematic functional surface marker screen, we find that early reprogramming-

244 When combined with high-throughput cell surface marker screening, this approach facilitates the

245 This study identifies FolR1 as a new cell surface marker selectively expressed in mesDA progenitor

246 These MDSCs express a cell surface marker signature (CD11b(+) Gr-1(+) Ly6C(+)) char

247 color flow cytometry panels to determine the surface marker signatures of oral neutrophil subsets in

248 (TICs) often requires screening of multiple surface markers, sometimes with opposite preferences.

249 reliant on the presence of well-defined cell surface markers specific for diverse progenitor populati

250 Hence it is important to find surface markers specific for Nestin(+) cells.

251 Although surface markers such as CD133 and CD44 have been success

252 be defined on the basis of the expression of surface markers such as CD34 and hematopoietin receptors

253 antibodies directed to cancer cell-specific surface markers, such as epithelial cell adhesion molecu

254 Identification of cell surface markers sufficient to purify Treg cells expanded

255 MSC with both endothelial and pericytic cell surface markers suppresses the homing of cancer cells to

256 s purpureas agglutinin (TPA) as a novel cell surface marker that allows for such delineation.

257 g flow cytometry, we identify CD26/DPP4 as a surface marker that allows isolation of this lineage.

258 CD20 is a B cell surface marker that is expressed in various stages in B

259 We also describe an alternative fibroblast surface marker that more accurately identifies the resid

260 We identified 33 transcripts encoding cell surface markers that are differentially expressed betwee

261 chemokine responses, and expression of cell surface markers that are related to T cell activation.

262 ork identifies a set of novel stage-specific surface markers that can be used as a complement to the

263 In conclusion, our findings identify 2 surface markers that can be used to facilitate the enric

264 e endoderm with the goal of identifying cell surface markers that can be used to track the developmen

265 We sought to delineate cell surface markers that could distinguish NK cells that had

266 We identify cell-surface markers that delineate a series of stress erythr

267 t act as roadblocks during reprogramming and surface markers that further enrich for cells prone to f

268 Surface markers that identify latently infected cells re

269 c programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammabili

270 Upon recognizing the targeted cell-surface marker, the APH enters the host cell via endocyt

271 dentification of lineage- and stage-specific surface markers, the continued identification of differe

272 to cancer cells presenting tumor-associated surface markers, thereby minimizing systemic toxicity.

273 have significant implications for Ly6C as a surface marker to distinguish functionally distinct CD4(

274 assay based on loss of expression of a cell surface marker to monitor epigenetic instability at the

275 Antibody panels recognize surface markers to delineate cell types simultaneously w

276 al in part independent of commonly used cell surface markers to discriminate effector and memory T ce

277 wever, been hindered by the lack of reliable surface markers to distinguish and isolate them for subs

278 ombine H2B-GFP-based pulse-chasing with cell-surface markers to distinguish quiescent from proliferat

279 thus far has been limited by the absence of surface markers to distinguish them.

280 We have used specific cell surface markers to examine the association of NG2 cells

281 ed green fluorescent protein (eGFP) and cell surface markers to FACS-isolate DeltaSox2-eGFP(+) GBCs,

282 We sought to validate a panel of surface markers to prospectively identify cardiac fibrob

283 rried out by quantification of multiple cell surface markers, transcription factors and cytokine prof

284 cytometry to simultaneously measure multiple surface markers, transcription factors, active signaling

285 of heterogeneous subpopulations in its cell surface markers, tumorigenicity, invasion and metastatic

286 nd immunized mice and displayed a pattern of surface markers typical for plasma cells.

287 The cells lacked expression of cell surface markers typically expressed by germinal center B

288 rom nonvaccinated infected mice exhibited M1 surface markers, vigorous proliferation, a substantial o

289 lon): CPMV nanoparticles enter cells via the surface marker vimentin, the nanoparticles target the en

290 cell populations from tumours in mice; these surface markers were also expressed on human PD1(hi) tum

291 fferential expression patterns of these cell surface markers were dependent on Ly49H recognition of i

292 Furthermore, surface markers were grouped into cell-type-specific cat

293 d a germline seminoma that share a CD38 cell-surface marker, which collectively defines likely progre

294 y identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90% of AM

295 CX3CR1, a cell surface marker whose expression is associated with endot

296 ing growth factor beta and beta-catenin, and surface markers with normal LPCs.

297 fied by comparing the expression of specific surface markers with PBMCs from healthy individuals.

298 Pre-DC share surface markers with plasmacytoid DC (pDC) but have dist

299 To identify novel surface markers with stage-specific expression patterns,

300 easured by the expression of CD38 and HLA-DR surface markers), with CD4 cell count and HIV viral load